Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral versus topical/intravenous tranexamic acid for blood loss reduction in total knee replacement
ACTRN12617000617369Phase 3Recruiting
- Sponsor
- John Flynn Private Hospital
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of tranexamic acid in knee osteoarthritis (OA) (2 arms), sponsored by John Flynn Private Hospital. Primary endpoint: Blood loss due to surgery. Started Aug 2017; status: recruiting.
02
Drugs
tranexamic acid
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on ACTRN12617000617369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000617369.